IDAI heads into its Q1 2026 results tonight carrying a visible contradiction: revenue grew 39% year-over-year, yet the company still missed both its EPS and sales estimates.
The numbers filed after the close tell the immediate story. Q1 EPS came in at -$0.42 against a -$0.39 estimate. Revenue of $756K fell short of the $1.05M consensus. That double miss lands against a stock that bounced 10% on May 14 — a reminder of just how sentiment-driven this micro-cap can be. The stock has still shed about 8% over the past month, trading at $2.31, and is down more than 7% on the week heading into the release. The peer group has moved in a different direction: correlated names like BTBT and PHUN posted weekly gains of 16% and 10% respectively, leaving IDAI a notable laggard in its own cohort.
Short selling pressure is modest but worth watching. Short interest is 3.9% of the free float — not an aggressive read, but it jumped roughly 21% in a single session on May 13, the sharpest one-day move in the 30-day window. Borrow costs have actually eased over the past month, running around 2.9% — roughly a third lower than the April peak near 4.8%. Availability has tightened sharply though: the lending pool moved from around 28–30% utilised at the start of May to 56% as of May 13, the highest reading since early April. That shift points to renewed demand for borrows in the days immediately before the print.
One structural backdrop complicates the story. In late April, Trust Stamp filed a prospectus to raise up to $100M through a public offering of Class A shares, warrants, and units — a large shelf relative to a company with this market cap. That overhang is material context for anyone assessing near-term dilution risk. The insider picture is quieter: the CEO, Gareth Genner, sold roughly $48K worth of shares on April 6, while also receiving a large stock award. The sales are small in dollar terms and carry low trade-significance scores. The top institutional holder cluster — Long Lake, Galloway, and Potomac — holds a combined ~19% of shares, but most last-reported dates run from late 2025, so it is unclear whether those positions have changed.
The only analyst data in the system comes from Maxim Group in September 2025 — too stale to be actionable at today's price of $2.31 against a then-raised target of $12.00. That gap is too wide to reconcile without a current update, so no analyst target is cited here.
The print is therefore less about the direction of revenue growth — 39% is real — and more about whether Trust Stamp can close the gap between its pipeline narrative and the recognised revenue line fast enough to justify holding through a dilutive capital raise.
See the live data behind this article on ORTEX.
Open IDAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
